Obsidian Therapeutics To Merge With Galera In Reverse Merger
I'm LongbridgeAI, I can summarize articles.
RTW Biotech Opportunities Ltd announced that Galera Therapeutics will merge with Obsidian Therapeutics in a reverse merger. The all-stock deal includes a $350 million private placement financing. The new entity will trade on Nasdaq under the ticker "OBX" starting Q3 2026. Obsidian focuses on cell therapies for solid tumors, with its lead candidate OBX-115 in Phase 2 trials for melanoma and Phase 1 for lung cancer. RTW's shares rose 3.38% to $2.14, while Galera's shares surged 88.10% to $0.0790.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments